ALX ONCOLOGY HOLDINGS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.21 USD | -4.37% |
|
+5.53% | +8.87% |
Presenter SpeechUnknown Attendee (Attendees)Hi, everyone. Welcome. It's a great to have everyo...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 immune checkpoint inhibitor and bridge the innate and adaptive immune system. Its product candidate, evorpacept, is a CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. It is engaged in focusing on combining evorpacept with anti-cancer antibodies, ADCs, and PD-1/PD-L1 immune checkpoint inhibitors. Cancer cells leverage CD47, a cell surface protein, as a donât eat me signal to evade macrophage phagocytosis or as a don't activate T-cells signal that prevents activation of T-cells by dendritic cells. It focuses on combining evorpacept with anti-cancer antibodies, ADCs, and PD-1/PD-L1 immune checkpoint inhibitors. It also has a preclinical program focused on developing ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer.
Calendar
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
16.21
USD
Average target price
21
USD
Spread / Average Target
+29.55%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +8.87% | 845M | |
| +3.91% | 109B | |
| +10.87% | 105B | |
| +1.28% | 22.25B | |
| -13.14% | 22.09B | |
| -7.05% | 18.68B | |
| -38.36% | 17.58B | |
| -10.66% | 16.85B | |
| +3.75% | 13.76B | |
| +36.70% | 12.46B |
- Stock Market
- Equities
- ALXO Stock
- News ALX Oncology Holdings Inc.
- Transcript : ALX Oncology Holdings Inc. Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-10-2023 10